GS 9876

Drug Profile

GS 9876

Alternative Names: GS-9876

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antirheumatics
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 01 Nov 2016 Gilead Sciences initiates enrolment in a phase I pharmacokinetics trial (In volunteers) in USA (PO, Tablet) (NCT02959138; ACTRN12616001548426p)
  • 01 Sep 2016 Phase-II clinical trials in Rheumatoid arthritis in USA (PO) (NCT02885181)
  • 26 Aug 2016 Gilead Sciences plans a phase II trial for Rheumatoid arthritis in USA, Bulgaria, Czech Republic, Hungary, Poland, Serbia, Ukraine (NCT02885181)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top